Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

<p>Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib. The prospective, observational REFINE study aimed to evaluate the safety and effectiveness...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2025-01-01
coleção:	Liver Cancer
Acesso em linha:	https://karger.com/article/doi/10.1159/000542285
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!